Disease–Disease / Drug–Disease Conflicts – Enabling Conditions – Pathological Spirals – HOW + DATA-to-operate solutions to expand the safety margin. [5]
Nguyen Dinh Quang • Vien gut Model – March 2026. [5]

Barnett et al. (Lancet 2012) demonstrated in over 1.7 million patients in Scotland that more than 42% of adults have at least two chronic conditions; this rate exceeds 80% for those over 80. In low-income groups, multimorbidity appears 10–15 years earlier. [5] However, the entire clinical medicine system — from physician training and specialty organization to guideline development — is still organized around a single-disease model. [5]

NICE (UK, 2016) issued a specific guideline for multimorbidity (NG56) because it recognized that single-disease guidelines were failing this patient group. [6] WHO and OECD have both confirmed this is a systemic gap requiring new solutions. [6] After years of acknowledging the gap, global medicine still lacks a specific operational model: knowing what to do (WHAT) but lacking guidance on how to do it (HOW) and what data is needed for decision-making (DATA-to-operate). [6]

This gap is not a personal difficulty for doctors — it is an architectural gap in global medicine. [6] The healthcare system is organized by specialty; patients move between specialties, but no one holds the “big picture” or bears final responsibility for the entire treatment plan. [6] Document B.5 is the starting point for a solution. [6]

Vien gut uses a threshold of ≥ 4 severe diseases with end-organ damage to distinguish “complex” from simple comorbidity. [7] Eighteen years of observation have identified seven characteristic dimensions of complexity: [7]

When four or more dimensions are present, the conventional treatment model faces structural limits. [8] In particular, the seventh dimension is the decisive differentiator: any event on one axis can collapse the remaining axes. [9] At Vien gut, patients aged 45–65 with rapid disease progression represent a significant proportion. [9]

When a patient simultaneously has severe gout + CKD G4 + heart failure + cirrhosis Child-Pugh B, single-disease guidelines conflict directly. [10] The original document analyzes 8 typical conflict pairs. For example: a gout flare in the context of CKD + heart failure — EULAR indicates NSAIDs/corticosteroids, but KDIGO + ESC list them as absolute contraindications. [10]

With 10 common chronic diseases, the number of four-disease combinations is 210, each with thousands of variants — there are insufficient RCTs or budgets to create evidence for every combination. [10] This is a methodological limit. [10] Vien gut calls this a “frame of reference shift”: guidelines from single diseases are applied to complex multimorbidity patients who were originally excluded from those clinical trials. [11]

The lack of three structural factors causes even expert multidisciplinary consultations to fail: (1) no common timeline; (2) no final decision-maker; (3) no continuous response mechanism. [12] This is the HOW gap that the Vien gut Model fills. [12]

The original document selected these two cases because they represent the final frontier where the Vien gut Model can protect the life axis and open a window of opportunity for outpatient conservative treatment. [12]

Enabling conditions (EC) are disorders (metabolic, endocrine, hematological) that are not the primary disease axis but determine the treatment safety margin. [15] Pathological spirals are mechanisms where deterioration in one axis drags down another. [16] Identifying and unraveling these spirals is the highest priority for the Clinical Conductor through DATA-to-operate. [16]

Conflict resolution principles: (1) prioritize protecting the life axis; (2) make decisions based on time-series trends; (3) record all decisions in a decision log/audit trail for traceability. [17] The model transforms conflict resolution from personal judgment into a structured, data-driven process. [17]

The safety margin in multimorbid patients is extremely narrow. [18] HOW + DATA-to-operate expands this margin by: precise risk stratification (T1–T4), continuous trend monitoring, and establishing individualized action thresholds. [18] Three targets are invited for verification: delaying dialysis for CKD G5; reducing heart failure decompensation; re-compensating Child-Pugh B cirrhosis. [19]

In the fragmented model, patients synthesize conflicting information themselves, leading to polypharmacy, increased emergencies, and a rapid slide into multi-organ decompensation. [19] The Vien gut Model adds an operational layer (Clinical Conductor, MDT, safety valves) and multi-axis time-series data to achieve treatment goals that individual guidelines cannot cover. [20, 21]